Treprostinil for pulmonary hypertension

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 2, 2004, Pages 183-191

  Vachiéry, Jean Luc ^a   Naeije, Robert ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Anorexigens; Congenital heart disease; Epoprostenol; HIV infection; Portal hypertension; Primary pulmonary hypertension; Prostacyclin; Pulmonary hypertension; Scleroderma; Treprostinil

Indexed keywords

ADENOSINE; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CICAPROST; CORTICOSTEROID DERIVATIVE; DIGOXIN ANTIBODY F(AB) FRAGMENT; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; LONG ACTING DRUG; NARCOTIC AGENT; NITRIC OXIDE; OXYGEN; PARACETAMOL; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PREDNISOLONE; PROCYCLIN; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SITAXSENTAN; UNIPROST; WARFARIN;

ABDOMINAL CRAMP; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FACE PAIN; FLUSHING; HEADACHE; HUMAN; INFUSION PUMP; INJECTION PAIN; LEG EDEMA; LIVER DYSFUNCTION; PULMONARY HYPERTENSION; QUALITY OF LIFE; SIDE EFFECT; VASODILATATION;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; INFUSION PUMPS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 2542516074     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.2.183     Document Type: Article

References (35)

1. Rubin LJ. Primary pulmonary hypertension. N. Engl. J. Med. 336, 111-117 (1997).
2. Humbert M, Nunes H, Sitbon O et al. Risk factors for pulmonary arterial hypertension. Clin. Chest Med. 22, 459-475 (2001).
3. Humbert M, Trembath RC. Genetics of pulmonary hypertension: from bench to bedside. Eur. Respir. J. 20, 741-749 (2003).
4. Fishman AP. Clinical classification of pulmonary hypertension. Clin. Chest Med. 22, 385-391 (2001).
5. Naeije R, Vachiéry JL. Medical treatment of pulmonary hypertension. Clin. Chest Med. 22, 517-527 (2001).
6. Higenbottam TW, Spiegelhalter D, Scott JP et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br. Heart J. 70, 366-370 (1993).
7. Barst, RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N. Engl J. Med. 334, 296-301 (1996).
8. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann. Intern. Med. 132, 425-434 (2000).
9. Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. 40, 780-788 (2002).
10. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106, 1477-1482 (2002).
11. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 99, 1858-1865 (1999).
12. Herve P, Lebrec D, Brenot F et al. Pulmonary vascular disorders in portal hypertension. Reu. Respir. J. 11, 1153-1166 (1998).
13. Nunes H, Humbert M, Sitbon O et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am. J. Resp. Crit. Care Med. 167, 1433-1439 (2003).
14. Nagaya N, Sasaki N, Ando M et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest 123, 338-343 (2003).
15. Galié N, Humbert M, Vachiéry JL et al. Effects of beraprost sodium, an oral prostacyclin analog, in patients with pulmonary arterial hypertension. J. Am. Coll. Cardiol. 39, 1496-1502 (2002).
16. Olschewsky H, Simonneau G, Galié N et al. Inhaled iloprost is an effective treatment for severe pulmonary hypertension. A double-blind, placebo-controlled, multicenter study. N. Engl. J. Med. 347, 322-329 (2002).
17. Simonneau G, Barst RJ, Galié N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analog, in patients with pulmonary arterial hypertension. Am. J. Respir. Crit. Care. Med. 162, 800-804 (2002).
18. Rubin LJ, Badesch RM, Barst R et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896-903 (2002).
19. Barst RJ, Langleben D, Frost A et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 169(4), 441-447 (2004).
20. Michelakis ED, Tymchak W, Noga M et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108, 2066-2069 (2003).
21. Steffen RP, de la Meta M. The effects of 15AU81, a chemically stable prostacyclin analog, on the cardiovascular and renin-angiotensin systems of anesthetized dogs. Prostaglandins Leukot. Essent. Fatty Acids 43, 277-286 (1991).
22. McNulty MJ, Sailstad JM, Steffen RP. The pharmacokinetics and pharmacodynamics of prostacyclin analog 15AU81 in anesthetized beagle dog. Prostaglandins Leukot. Essent. Fatty Acids 48, 159-166 (1993).
23. Remodulin™, Treprostinil sodium. Investigators Brochure. United Therapeutics Corporation, MD, USA (2002).
24. Wade M, Baker FJ, Roscigno R et al. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. J. Clin. Pharmacol. 44, 83-88 (2004).
25. Wade M, Hunt TL, Lai AA. Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharinacokinetics of warfarin. J. Cardiovasc. Pharmacol. 41, 908-9015 (2003).
26. Phares KR, Weiser WE, Miller SP, Myers MA, Wade M. Stability and preservative effectiveness of treprostinil sodium after dilution in common intravenous diluents. Am. J. Health Syst. Pharm. 60, 916-922 (2003).
27. Eddahibi S, Morrell N, d'Ortho MP, Naeije R, Adnot S. Pathobiology of pulmonary arterial hypertension. Eur. Respir. J. 20, 1559-1572 (2002).
28. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ. Tinker Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am. J. Respir. Cell Mol. Biol. 26, 194-201 (2002).
29. Raychaudhuri B, Malur A, Bonfield TL et al. The prostacyclin analog treprostinil blocks NFκB nuclear translocation in human alveolar macrophages. J. Biol. Chem. 277, 33344-33348 (2002).
30. McLaughlin VV, Gaine SP, Barst RJ et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J. Cardiovasc. Pharmacol. 41, 293-299 (2003).
31. Galie N, Manes A, Branzi A. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur. Respir. J. 20, 1037-1049 (2002).
32. Gibbs JSR, Arneson CF. Chronic infusion of treprostinil is safe and appears to prolong survival over a three-year period in patients with pulmonary arterial hypertension Circulation 106 (Suppl. II), 575 (2002).
33. Vachiery JL, Gautier MT, Huez S, Retailleau K, Naeije R. Long-term subcutaneous treprostinil therapy evokes both survival benefits and continuous dose-dependent efficacy improvements in patients with pulmonary arterial hypertension. Circulation 108 (Suppl. IV) 400, (2003).
34. Vachiery JL, Hill N, Zwicke D et al. Transitioning from iv. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 121 1561-1565 (2003).
35. Sitbon O, Humbert M, Ioos V et al. Who benefits from long-term calcium-channel blocker therapy in primary pulmonary hypertension? Am. J. Resp. Crit. Care Med. 167, A440 (2003).